Ann Rheum Dis 63:1538-1543 doi:10.1136/ard.2004.024737
  • Review

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

  1. K L Hyrich,
  2. A J Silman,
  3. K D Watson,
  4. D P M Symmons
  1. ARC Epidemiology Unit, University of Manchester, UK
  1. Correspondence to:
    Professor A J Silman
    ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK;
  • Accepted 20 June 2004
  • Published Online First 8 July 2004


Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.